Quote | Scopus BioPharma Inc. (NASDAQ:SCPS)
Last: | $0.1682 |
---|---|
Change Percent: | 26.49% |
Open: | $0.25 |
Close: | $0.1682 |
High: | $0.25 |
Low: | $0.1682 |
Volume: | 3,387,508 |
Last Trade Date Time: | 12/16/2022 03:40:50 pm |
News | Scopus BioPharma Inc. (NASDAQ:SCPS)
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...
Message Board Posts | Scopus BioPharma Inc. (NASDAQ:SCPS)
Subject | By | Source | When |
---|---|---|---|
$SCPS: effective Dec. 19,2022 $SCPS delisted from the | Renee | investorshub | 12/16/2022 10:14:10 PM |
znewcar1: $SCPS 44% v31,4M c.3401 f21,0M pmh..6 hod.5794 then fell | znewcar1 | investorshangout | 12/16/2022 4:06:11 AM |
Wonder why the spike today? | RAlbert | investorshub | 12/15/2022 1:52:19 PM |
SITC started 2 days ago November 8 and | FACT-MASTER | investorshub | 11/11/2022 4:00:42 AM |
NEWS SITC 2022 : | FACT-MASTER | investorshub | 11/10/2022 11:13:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Scopus BioPharma Inc. Company Name:
SCPS Stock Symbol:
NASDAQ Market:
DUET-102 in Combination with PD-1 Blockade Demonstrates Significant Anti-Tumor Activity in Models of Malignant Glioma Data Suggests Benefits of Combinations of DUET-102 with Other T-Cell Based Immunotherapies, such as CAR-Ts NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus B...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: "SCPS"), a biotechnology company developing transformational therapeut...
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS ”) , a biotechnology company developing transformational therapeutics for serious diseases with significant unmet medical need, and its subsidiary, Duet BioTherapeutics Inc., which is...